Molecular Partners Ag (MOLN) Capital Expenditures (2020 - 2025)

Molecular Partners Ag (MOLN) has reported Capital Expenditures for 6 consecutive years, with -$173912.6 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Capital Expenditures fell 12.02% year-over-year to -$173912.6 in Q4 2025; TTM through Dec 2025 was -$826911.7, a 3.14% decrease from a year earlier, with the FY2025 full-year figure at -$861175.7, down 7.46% from the prior year.
• Capital Expenditures was -$173912.6 for Q4 2025 at Molecular Partners Ag, down from -$38753.4 in the prior quarter.
• Over five years, Capital Expenditures peaked at $376817.3 in Q1 2022 and troughed at -$1.1 million in Q3 2021.
• A 5-year average of -$224508.9 and a median of -$164579.8 in 2024 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 274.38% in 2022, down 425.7% in 2022.
• Over 5 years, Capital Expenditures stood at -$272210.0 in 2021, then tumbled by 116.21% to -$588558.4 in 2022, then surged by 42.92% to -$335951.6 in 2023, then surged by 53.79% to -$155247.0 in 2024, then dropped by 12.02% to -$173912.6 in 2025.
• The last three Capital Expenditures figures came in at -$173912.6 (Q4 2025), -$38753.4 (Q3 2025), and -$115957.5 (Q2 2025), per Business Quant data.